Details

Details

Title Clinical predictors of benefit from pemetrexed in patients with metastatic non small cell lung cancer

IRB CHRV0090

Hospital Main Campus

Stage N/A

Phase N/A

Disease Lung

Drug Pemetrexed

Description

Description

Primary
  1. The primary goal of this study is to identify clinical and pathologic characteristics associated with extended progression-free survival in patients with metastatic NSCLC patients treated with pemetrexed.
Secondary
  1. Secondary goals are to examine factors associated with objective response and pemetrexed-related toxicity
Inclusion Criteria

Inclusion Criteria

  1. Patients must have a proven diagnosis of metastatic NSCLC
  2. Documented treatment with pemetrexed in the metastatic setting
Exclusion Criteria

Exclusion Criteria

  1. Patients who have received pemetrexed as part of definitive concurrent chemoradiation for locally advanced NSCLC, or as adjuvant treatment after resection for early stage NSCLC